Last updated: May 5, 2023
Sponsor: University College, London
Overall Status: Completed
Phase
3
Condition
Depression
Treatment
Escitalopram
Placebo
Nortriptyline
Clinical Study ID
NCT03652870
18/0279
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with a diagnosis of idiopathic Parkinson's Disease, based on a history andneurological exam performed by the enrolling investigator with presence of at leasttwo of the three cardinal signs of Parkinson's Disease: rigidity, bradykinesia, andrest tremor with no evidence of diagnostic alternatives. Patients who have beentreated with levodopa must have demonstrated a clear response.
- Aged 18 years old or above
- Fulfilling diagnostic (DSM-V) criteria for a depressive disorder (i.e., majordepressive disorder or persistent depressive disorder) or operationally definedsubsyndromal depression (presence of two or more depressive symptoms at threshold orsubthreshold levels, at least one of which has to include depressed mood or anhedonia
- Beck Depression Inventory-II (BDI-II) score ≥14
- Written informed consent provided
- Treatment with antiparkinsonian medication is optimised or stable for at least 4 weeksbefore date of randomisation and there are no plans to change up to primary endpoint (8 weeks).
Exclusion
Exclusion Criteria:
- Women who are pregnant, breastfeeding or of childbearing potential without effectivecontraception (hormonal or barrier method of birth control; or abstinence)
- Patients not able to communicate answers to the self-rating questionnaires
- Patients with Montreal Cognitive Assessment (MoCA) score <16 or without capacity toconsent
- Treatment with an antidepressant within 4 weeks of enrolment (except for a small doseof amitriptyline up to 50 mg for indications other than depression)
- Patients with known severe liver failure.
- Absolute contraindications to escitalopram or nortriptyline. These include:
- Patients with known QT-interval prolongation or congenital long QT syndrome.
- Recent myocardial infarction (<3 months), any degree of heart block or othercardiac arrhythmias precluding treatment with nortriptyline or escitalopramaccording to clinical judgement.
- Medications contraindicated on nortriptyline or escitalopram. These include:
- Non-selective and selective irreversible monoamine oxidase inhibitors (MAOIs)within 14 days. However, the antiparkinsonian selective reversible MAO-Binhibitors rasagiline, selegiline and safinamide are not contraindicated.
- Concomitant QT prolonging drugs, including domperidone, apomorphine at high doses (single dose or hourly rate of >6mg), certain neuroleptics (not quetiapine orclozapine), quinine, class IA and III antiarrhythmics (amiodarone, dronedaroneand disopyramide), the antihistamines astemizole, mizolastine, the antimicrobialagents sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malariantreatment),and some antiretrovirals.
- Patients indicating active suicidal ideation or intent on the BDI-II item 9 and who,after clinical review of risk using the standardised Suicide Risk Management Protocol,need to be referred for immediate treatment.
- Participation in another clinical trial of an investigational medicinal product ordevice within the last 30 days.
- Any clinical condition which in the opinion/ clinical judgement of the investigatorwould make the patient unsuitable for the trial due to safety concerns.
Study Design
Total Participants: 52
Treatment Group(s): 3
Primary Treatment: Escitalopram
Phase: 3
Study Start date:
March 05, 2021
Estimated Completion Date:
April 30, 2023
Study Description
Connect with a study center
Royal Free London NHS Foundation Trust
London, NW3 2QG
United KingdomSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.